title: WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
abstract: We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
  
  
  METHODS
  Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.
authors.affiliation: Department of Obstetrics and Gynecology, Kanazawa University, Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8640 Japan. satoshi.dohi1018@gmail.com
authors.forename: Satoshi
authors.initials: S
authors.lastname: Dohi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ohno
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Ohno
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takakura
authors.forename: Satoru
authors.initials: S
authors.lastname: Kyo
authors.forename: Gen-Ichiro
authors.initials: G
authors.lastname: Soma
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Masaki
authors.initials: M
authors.lastname: Inoue
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D000077143:Docetaxel; D005260:Female; D015234:HLA-A Antigens / Q000008:administration & dosage / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D016233:Immunotherapy, Active; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D009852:Omentum / Q000473:pathology / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D043823:Taxoids / Q000008:administration & dosage; D047368:Tumor Burden; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000627:therapeutic use; D025721:WT1 Proteins / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D019496:Cancer Vaccines; D015234:HLA-A Antigens; C438506:HLA-A*24:02 antigen; D059871:HLA-A24 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D010446:Peptide Fragments; D043823:Taxoids; D022223:Vaccines, Subunit; D025721:WT1 Proteins; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel